The patent buyout price for human papilloma virus (HPV) vaccine and the ratio of R&D costs to the patent value.
Human papillomavirus (HPV) is responsible for almost all of the 570,000 new cases of cervical cancer and approximately 311,000 deaths per year. HPV vaccination is an integral component of the World Health Organization's (WHO) global strategy to fight the disease. However, high vaccine prices en...
Saved in:
| Main Authors: | Mario Songane, Volker Grossmann |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2021-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0244722&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Patent suspension on the COVID-19 vaccine in Indonesian patent law perspective
by: Vania Lutfi Safira Erlangga, et al.
Published: (2023-12-01) -
Patents and Patent Searching
by: Alice K. Kawakami
Published: (1998-08-01) -
Pricing the Audit Risk of Innovation: Intangibles and Patents
by: Daqun Zhang, et al.
Published: (2025-03-01) -
Human Papilloma Virus (HPV) vaccination in Italy: towards new perspectives and new challenges
by: Vittoria Colamesta, et al.
Published: (2018-12-01) -
Cervical Cancer and Human Papilloma Virus (HPV) Vaccines: A primer for General Physicians
by: Pooja Dwivedi, et al.
Published: (2024-05-01)